23 February 2009
Dupuytren’s contracture and phenobarbital: Our case reports and review of the literature
Massimiliano Tripoli, Adriana Cordova, Pietro Napoli, Mario Cherubino, Francesco MoschellaAm J Case Rep 2009; 10:18-21 :: ID: 869590
Abstract
Background: Dupuytren’s contracture is a fibroproliferative condition involving the superficial palmar fascia, leading to a progressive and irreversible flexion of the fingers. In literature, there are different opinions regarding the phenobarbital, a common antiepileptic drug, and its effective role in the genesis and development of Dupuytren’s disease. In our this retrospective study the association between phenobarbital and Dupuytren’s contracture is discussed.
Case Reports: Three patients in treatment with phenobarbital who had no others significant risk factors for Dupuytren’s contracture were included in this study. The disease occurred after one to four years of drug therapy, at dosage of 100 mg/day. After surgery, Dupuytren’s disease showed different evolutions in relation to dosage and type of antiepileptic drug used.
Conclusions: We believe that phenobarbital causes a dose and time-dipendent profibrotic effect. We notice a clinical regression when phenobarbital was substituted by carbamazepine, maintaining the same dose (100 mg/day). This data confirms that not all the antiepileptic drugs are implicated in palmar fibrosis, and suggests that, according to the efficacy and adverse effects, the administration of benzodiazepine reduces the risk of Dupuytren’s recurrence.
Keywords: Dupuytren's Contracture, Phenobarbital, Epilepsy
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947567
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.948238
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947782
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947794
Most Viewed Current Articles
21 Jun 2024 : Case report
100,489
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
53,790
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
36,376
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
07 Jul 2023 : Case report
25,034
DOI :10.12659/AJCR.940200
Am J Case Rep 2023; 24:e940200